ViennaLab is now releasing the first series of multiplex (mpx) RealFast™ Assays. The ViennaLab multiplex RealFast™ Assays allow to genotype two loci simultaneously and thus save costs and sample material.
The following multiplex RealFast™ Assays will become available as of 1st week of May 2018:
The CYP2C9 mpx RealFast™ Assay is designed for the simultaneous detection of the c.430C>T (CYP2C9*2) and c.1075A>C (CYP2C9*3) polymorphisms in the human CYP2C9 gene. Both variants of the CYP2C9 enzyme, *2 and *3, exhibit decreased function leading to poor metabolism (PM) phenotypes for various drugs. Patients with low enzyme activity are at risk of adverse drug reactions or therapeutic failure, particularly for CYP2C9 substrates with a narrow therapeutic window, such as S-warfarin or phenytoin. The kit is designed to identify patients carrying one or two variants of the CYP2C9 *2 or *3 variants.
The Alpha-1 antitrypsin (AAT) mpx RealFast™ Assay is designed for the simultaneous detection of the protease inhibitor (PI) variants *S and *Z of the SERPINA1 gene. These are the most frequent alleles associated with alpha-1 antitrypsin deficiency. The kit is intended for use as a diagnostic tool to identify alpha-1 antitrypsin deficient patients carrying a PI*S or PI*Z allele.
Subscribe to our newsletter!